X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (126) 126
female (100) 100
oncology (97) 97
male (90) 90
middle aged (87) 87
index medicus (82) 82
aged (80) 80
adult (60) 60
physics (56) 56
lung cancer (55) 55
lung neoplasms - drug therapy (49) 49
chemotherapy (48) 48
cancer (41) 41
lung neoplasms - pathology (41) 41
aged, 80 and over (36) 36
carcinoma, non-small-cell lung - drug therapy (35) 35
mutation (33) 33
respiratory system (32) 32
electricity (31) 31
gefitinib (31) 31
measuring (29) 29
testing (29) 29
performing operations (28) 28
transporting (28) 28
chemistry (26) 26
lung cancer, non-small cell (26) 26
treatment outcome (26) 26
metallurgy (24) 24
antineoplastic combined chemotherapy protocols - therapeutic use (23) 23
carcinoma, non-small-cell lung - pathology (23) 23
care and treatment (23) 23
neoplasm staging (23) 23
patients (23) 23
general tagging of cross-sectional technologies spanning over several sections of the ipc (22) 22
general tagging of new technological developments (22) 22
non-small cell lung cancer (22) 22
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (22) 22
therapy (22) 22
lung neoplasms - mortality (21) 21
analysis (20) 20
animals (20) 20
human necessities (20) 20
metastasis (20) 20
lung neoplasms - genetics (19) 19
research (19) 19
carcinoma, non-small-cell lung - mortality (18) 18
cancer therapies (17) 17
disease-free survival (17) 17
japan (17) 17
medicine & public health (17) 17
trial (17) 17
investigating or analysing materials by determining theirchemical or physical properties (16) 16
antineoplastic agents - therapeutic use (15) 15
carboplatin (15) 15
protein kinase inhibitors - therapeutic use (15) 15
rats (15) 15
survival (15) 15
tumors (15) 15
tyrosine (15) 15
acquired-resistance (14) 14
basic electric elements (14) 14
docetaxel (14) 14
electric communication technique (14) 14
heating (14) 14
prognosis (14) 14
retrospective studies (14) 14
technologies or applications for mitigation or adaptation againstclimate change (14) 14
blasting (13) 13
calculating (13) 13
computing (13) 13
counting (13) 13
erlotinib (13) 13
genetic aspects (13) 13
hematology, oncology and palliative medicine (13) 13
lighting (13) 13
lung neoplasms - diagnosis (13) 13
mechanical engineering (13) 13
non-small cell lung carcinoma (13) 13
optics (13) 13
pulmonary/respiratory (13) 13
survival rate (13) 13
testing static or dynamic balance of machines orstructures (13) 13
testing structures or apparatus not otherwise provided for (13) 13
tumor cells, cultured (13) 13
weapons (13) 13
adenocarcinoma - pathology (12) 12
antineoplastic combined chemotherapy protocols - adverse effects (12) 12
combustion engines (12) 12
hot-gas or combustion-product engine plants (12) 12
nivolumab (12) 12
oncology, experimental (12) 12
open-label (12) 12
pictorial communication, e.g. television (12) 12
protein-tyrosine kinase (12) 12
receptor, epidermal growth factor - genetics (12) 12
climate change mitigation technologies related totransportation (11) 11
diagnosis (11) 11
epidermal growth factor receptors (11) 11
hygiene (11) 11
medical or veterinary science (11) 11
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2017, Volume 390, Issue 10089, pp. 29 - 39
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2018, Volume 378, Issue 2, pp. 113 - 125
In 556 patients with previously untreated lung cancer bearing EGFR mutations, osimertinib and the first-generation EGFR inhibitors erlotinib and gefitinib had... 
1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | PHASE-III | ACQUIRED-RESISTANCE | OPEN-LABEL | CNS RESPONSE | AZD9291 | CHEMOTHERAPY | ERLOTINIB | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Gefitinib | Lung Neoplasms - genetics | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Survival Rate | Piperazines - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Piperazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Aged | Erlotinib Hydrochloride - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Treatment outcome | Cancer patients | Care and treatment | Lung cancer, Non-small cell | Analysis | Tyrosine | Medical research | Epidermal growth factor receptors | Lung cancer | Clinical trials | Non-small cell lung carcinoma | Oncology | Metastasis | Gene deletion | Patients | Cancer therapies | Clinical outcomes | Chemotherapy | Epidermal growth factor | Clonal deletion | Protein-tyrosine kinase receptors | Protein-tyrosine kinase | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 8, pp. 1147 - 1157
Journal Article
Cancer Science, ISSN 1347-9032, 03/2016, Volume 107, Issue 3, pp. 353 - 358
Circulating tumor DNA (ctDNA) is an emerging field of cancer research. For lung cancer, non‐invasive genotyping of EGFR is the foremost application. The... 
lung cancer | Carcinoembryonic antigen | epidermal growth factor receptor tyrosine kinase inhibitor | massively parallel DNA sequencer | circulating tumor DNA | Epidermal growth factor receptor tyrosine kinase inhibitor | Massively parallel DNA sequencer | Lung cancer | Circulating tumor DNA | GEFITINIB | PLASMA DNA | ACQUIRED-RESISTANCE | EGFR MUTATIONS | EMERGENCE | CELL LUNG-CANCER | HETEROGENEITY | THERAPY | ONCOLOGY | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Humans | Middle Aged | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Mutation, Missense | Biomarkers, Tumor - blood | DNA, Neoplasm - blood | DNA Mutational Analysis | Protein Kinase Inhibitors - therapeutic use | Aged, 80 and over | Female | Aged | Antineoplastic Agents - pharmacology | Biomarkers, Tumor - genetics | Lung Neoplasms - blood | Protein Kinase Inhibitors - pharmacology | DNA, Neoplasm - genetics | Tyrosine | Development and progression | Epidermal growth factor | Multiprocessing | Analysis | DNA | Phenols | Genetic research | Genetic aspects | Nucleotide sequencing | CEA (Oncology) | Cancer | DNA sequencing | Plasma | Disease | Laboratories | Cytotoxicity | Gene deletion | Kinases | Clonal deletion | Protein-tyrosine kinase receptors | Protein-tyrosine kinase | Deoxyribonucleic acid--DNA | Subpopulations | Nucleotide sequence | Epidermal growth factor receptors | Invasiveness | Patients | Studies | Genotyping | Biopsy | Mutation | Genetic testing | Cytotoxic agents | Tumors | Original
Journal Article
PLoS ONE, ISSN 1932-6203, 2011, Volume 6, Issue 9, p. e24143
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 1, pp. 106 - 113
Journal Article